PCR Solutions

Epigenetics

Epigenetics research and its significance in cancer

Introduction to epigenetics and techniques There has been a great interest in the study of epigenetic mechanisms and DNA methylation in many areas of research, including DNA repair, cell cycle control, developmental biology, cancer research, identification of biomarkers, predisposition factors and potential drug targets. Lately I’ve been immersed in this field via my close work… Read article →


S_5000_OneStep_iS18752900 (3)

8 challenges to successful one-step RT-PCR

Once you’ve decided to do an RT-PCR experiment, you have a choice: one step or two? Both options have advantages and disadvantages, so it depends on your experimental goals. In 2-step RT-PCR, reverse transcription and PCR take place in different tubes, enabling the optimization of each separate reaction. This is useful if you have a… Read article →


Quality control PCRD

The reproducibility crisis: what can we do?

There’s a growing trend of irreproducible results in biomedical research. In a previous post, Kurchi Bhattacharya reported on recent studies finding that a surprising number of scientists could not only not reproduce the results of their colleagues, but many found their own results difficult to reproduce as well. Much of the reproducibility problem likely has… Read article →


Plasmid eGuide

Get the most from your plasmids – the eGuide way!

In 1986, the launch of the QIAGEN Plasmid Maxi Purification Kit meant an incredible acceleration in time to result: from 2 days to just 2 hours! Now our 73 QIAGEN Plasmid family members are used worldwide for remarkable research. To help meet the need for easy selection of the correct tool to optimize your plasmid purification… Read article →


Tcell_WBC_SingleCell_BLUE_BG_580x200

The PD1 race picks up pace

If you’ve been following developments in cancer immunotherapy closely, you’ve probably heard of programmed death 1 (PD1/PDCD1, also known as CD279) and PDL1 (CD274). Their interaction is at the center of new immune checkpoint-targeting therapies coming out of the pharmaceutical industry, such as Bristol-Myers Squibb’s nivolumab and Merck’s pembrolizumab (1, 5). What are PD1 and PDL1, and… Read article →